Relay Therapeutics, Inc.
Every calculator, already run for RLAY
Open the full toolkit →You have the numbers on RLAY. Get the argument.
A written report on which of these readings actually decide the outcome for Relay Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering RLAYAnalyst Price Target Disagreement for Relay Therapeutics, Inc.
Wall Street's bull case implies +69% from the current price; the bear case implies +5%. A 63% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RLAY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a recep…
RLAY — frequently asked
Is RLAY a buy right now?
Wall Street's consensus rating on Relay Therapeutics, Inc. is Strong Buy across 13 analysts, with a mean price target of $27.58 (+45% vs. the current $18.96). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is RLAY's next earnings date?
Relay Therapeutics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full RLAY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Relay Therapeutics, Inc.?
Analysts covering Relay Therapeutics, Inc. (RLAY) range from a bear-case target of $20.00 to a bull-case high of $32.00, with a mean consensus target of $27.58 across 12 analysts. The spread of $12.00 (63% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Relay Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Relay Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RLAY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Relay Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.